Pancreatic Cancer Research

ResearcherUniversity of FreiburgActive in the last 2 years

Ralph Fritsch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9639-3213; OpenAlex author ID A5013636749, A5136088542. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 6 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 19

  1. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  2. Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-026-19841-5↗
  3. ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-anal… Co-author DOI 10.1245/s10434-026-19926-1↗
  4. A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer. Last author DOI 10.1016/j.esmogo.2025.100134↗
  5. Real-World Advances in Metastatic Pancreatic Cancer Treatment in the Pre-Molecular Era: A Retrospective Single-Center Analysis 2010-2018. Last author DOI 10.1159/000546307↗
  6. Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities. Co-author DOI 10.1016/j.canlet.2024.216650↗
  7. Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer: A Preliminary Study. Last author DOI 10.3390/diagnostics15010049↗
  8. Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients? Co-author DOI 10.3390/cancers15174398↗
  9. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open rand… Co-author DOI 10.1186/s13014-022-01988-6↗
  10. Treatment landscape of metastatic pancreatic cancer. Co-author DOI 10.1016/j.ctrv.2021.102180↗
  11. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-021-86779-x↗
  12. Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer Co-author DOI 10.1093/bjs/znaa116↗
  13. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  14. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer. Last author DOI 10.1186/s12885-020-07736-x↗
  15. β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. Co-author DOI 10.14309/ctg.0000000000000395↗
  16. Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures. Co-author DOI 10.3390/cancers12061440↗
  17. Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fgene.2018.00108↗
  18. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Co-author DOI 10.1038/s41598-017-04601-z↗
  19. Author Correction: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Co-author DOI 10.1038/s41598-017-14870-3↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Saskia Hussung · 14 shared papers, 2017–2025 · strength 2.14
  2. Uwe A. Wittel · 6 shared papers, 2018–2024 · strength 0.85
  3. José Oberholzer · 3 shared papers, 2026 · strength 0.69
  4. Ning Pu · 3 shared papers, 2026 · strength 0.69
  5. Dilmurodjon Eshmuminov · 3 shared papers, 2026 · strength 0.69
  6. Víctor López‐López · 3 shared papers, 2026 · strength 0.69
  7. Michael C. Frey · 3 shared papers, 2026 · strength 0.69
  8. So Heun Lee · 3 shared papers, 2026 · strength 0.69
  9. Changhoon Yoo · 3 shared papers, 2026 · strength 0.69
  10. Melanie Boerries · 4 shared papers, 2018–2024 · strength 0.59
  11. Daniela M. Lenggenhager · 3 shared papers, 2021–2025 · strength 0.55
  12. Bradley Norman Reames · 2 shared papers, 2026 · strength 0.50
  13. Haleh Amirian · 2 shared papers, 2026 · strength 0.50
  14. Chunmeng Zhang · 2 shared papers, 2026 · strength 0.50
  15. Jashodeep Datta · 2 shared papers, 2026 · strength 0.50
  16. Chantal Pauli · 2 shared papers, 2024–2025 · strength 0.43
  17. Anina Julia Ruth Mäder · 1 shared paper, 2025 · strength 0.37
  18. Sara De Dosso · 2 shared papers, 2021–2023 · strength 0.30
  19. Julian Hipp · 2 shared papers, 2021 · strength 0.26
  20. Lukas M. Braun · 2 shared papers, 2020–2021 · strength 0.26
  21. Sabrina Steiner · 1 shared paper, 2024 · strength 0.21
  22. Syed A. Ahmad · 1 shared paper, 2026 · strength 0.19
  23. Giuseppe Malleo · 1 shared paper, 2026 · strength 0.19
  24. Gregory C. Wilson · 1 shared paper, 2026 · strength 0.19
  25. Ryan K. Schmocker · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.